CMV-seronegative B-CLL patients show a trend toward increased overall survival compared with the CMV-seropositive group. Kaplan-Meier analysis was used to determine the influence of CMV seropositivity on survival in patients with B-CLL. A log-rank test was used to test the difference between the 2 survival curves. The median survival of the CMV-seronegative group was estimated at 157 months compared with 112 months for the CMV-seropositive patients (P = .42)